Author: KCCure

Translocation Renal Cell Carcinoma (tRCC) Research Initiative

Translocation renal cell carcinoma (tRCC) is a rare subtype of renal cell carcinoma occurring in less than 5 percent of patients. Initially found primarily in children, incidence of tRCC found in adults is rising. Because it is so rare, research to identify the best treatments for tRCC patients is severely lacking.  The Translocation RCC Research Initiative (TRRI) is worki...

A Day of Kidney Cancer Talk – June 20th – World Kidney Cancer Day

KCCure and Kidney Cancer Canada join forces to bring patients and caregivers A DAY OF KIDNEY CANCER TALK on World Kidney Cancer Day! A DAY OF KIDNEY CANCER TALK is 45-minute “talk” sessions scheduled throughout the day with kidney cancer specialists in Canada, United States and Europe. We’ll be featuring 45 minute sessions throughout the day with experts from the U.S. and Canada. No presenta...

Voice of Kidney Cancer – Carol’s Story

In April 2019 the Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).  We’re grateful to brave patients like Carol who participated in a clinical trial and helped make this treatment a reality for advanced RCC patients.   I have been retired for more than 5...

NIH Clear Cell Kidney Cancer Trial

NIH Trial – HERV-E TCR Transduced Autologous T Cells in People with Metastatic Clear Cell Kidney Cancer.    Good News!  Since I last shared news of this exciting clear cell kidney cancer trial it has continued to actively recruit.  If you are interested there are still spots available.  Eligibility criteria include: Being at least 18, having clear cell RCC, measurabl...

Voice of Kidney Cancer – John Coulthard

Never give up! I was diagnosed April 2016 with bilateral stage 4 RCC at 63 years old. Zero symptoms so it was a bit of a surprise. Two surgeries – a full nephrectomy and a partial – by then one tumor was basketball sized, at Ochsner in New Orleans. Luckily I was able to retire and get full disability and went onto oral medication (Cabometyx). At this point I had not really realized tha...

KCCURE WELCOMES APPROVAL OF ADDITIONAL COMBINATION THERAPY FOR ADVANCED RENAL CELL CARCINOMA

Washington, DC, ——– – The Kidney Cancer Research Alliance(KCCure) applauds the approval of yet another treatment for advanced renal cell carcinoma by the U.S. Food and Drug Administration (FDA). The latest approved therapy combines EMD Serono’s Avelumab (BAVENCIO) with Pfizer’s axitinib (INLYTA) as first-line treatment for patients with advanced renal cell carcinoma (RCC).  Axiti...

Voice of Kidney Cancer – Caroline Sample

My kidney cancer journey was preceded by breast cancer, which was caught early through a routine mammogram. After two surgeries I returned to work in January 2010, the same month I celebrated my 60th birthday and my cancer-free status. We had learned much, including how to advocate for ourselves, ask for help and support and to celebrate every bit of good news. The thrill didn’t last long. One mon...

Voice of Kidney Cancer – Bryn Jones

Bryn is a member of KCCure’s Benign Renal Mass Community.  He shares his story of being diagnosed with kidney cancer, only to learn following surgery that his masses were benign oncocytoma. Many patients struggle with anxiety and guilt after such an experience. KCCure is committed to supporting these patients and working to better identify gaps in care for newly diagnosed patients preparing ...

KCCURE APPLAUDS FDA APPROVAL OF NEW COMBINATION THERAPY FOR ADVANCED KIDNEY CANCER

Washington, DC, ——– – The Kidney Cancer Research Alliance (KCCure) welcomes the U.S. Food and Drug Administration (FDA) decision to approve pembrolizumab (KEYTRUDA) in combination with axitinib (INLYTA) as first-line treatment for patients with advanced renal cell carcinoma (RCC).   Pembrolizumab is an anti-PD-1 checkpoint inhibitor that helps the immune syste...

Non-Clear Cell Response Rate Chart

This chart lays out non-clear cell response rates for two kidney cancer clinical trials that were presented at ASCO-GU 2019. The Keynote 427 trial for pembrolizumab (Keytruda) as monotherapy and the Calypso trial combining savolitinib (MET inhibitor) and durvalumab (PD-1 inhibitor).

Voice of Kidney Cancer – Rahson Taylor

Rahson is battling a rare form of kidney cancer called Hereditary Leiomyomatosis and Renal Cell Cancer or HLRCC.   HLRCC is a rare genetic condition that increases the risk of developing kidney cancer.  HLRCC is caused by mutations in a gene called fumarate hydratase (FH) gene. Rahson’s journey began after experiencing symptoms of nausea, significant lower back pain, and blood in his urine. ...

Voices of Kidney Cancer

KCCure wishes to thank everyone in the kidney cancer community for sharing their voices in March for Kidney Cancer Awareness Month. We received more stories than there are days in March!!  If you sent us a story and it has not been published yet, we have it saved for publication at a later date. Why do we publish stories? Each story is a reminder that no one is alone in the fight against kidney ca...

Lost Password

Register

Subscribe for updates!